MVA-member Novo Nordisk invests DKK 5.4 bn DKK in expansion of clinical manufacturing facilities in Bagsværd, Denmark

Nov 22, 2022

As described in more detail in the analysis Life Science in Eastern Denmark, published in May life science investments are booming in the Medicon Valley region. In addition to substantial previous investments Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities.

“This investment in expanding our clinical API capacity in Bagsværd is an important step to ensure the continuous progress of our development pipeline. Increasing our API capacity in R&D will be a key enabler in bringing new innovations to the market, and meet the future demand of our patients”, said Jesper Bøving, senior vice president, CMC Development, Novo Nordisk.

The investment project is expected to be finalised in 2024 and will create around 160 new jobs. With the planned expansion MVA-member, Gladsaxe Municipality, where the city of Bagsværd and the Novo Nordisk HQ is located, will further cement it´s position as the leading life science municipality in the Medicon Valley region.

Most recent news